文章：

针对PD-1/PD-L1抑制剂耐药的非小细胞肺癌（NSCLC）的新型免疫治疗策略

Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors

原文发布日期：25 October 2024

DOI: 10.3390/cancers16213603

类型: Article

开放获取: 是

英文摘要：

Immunotherapy with PD-1/PD-L1 inhibitors is the standard method of care for the treatment of newly diagnosed advanced or metastatic NSCLC, with or without chemotherapy. Many tumors, however, develop resistance to these immunotherapy agents. There is a need to develop more effective therapies for patients with metastatic NSCLC in the second-line setting and beyond. In this review, we present an overview of novel immunotherapies being investigated regarding the treatment of these patients. We summarize completed, as well as ongoing, trials investigating these therapies as monotherapy or in combination with PD-1/PD-L1 inhibitors. These include immune co-stimulatory antibodies, T-cell agonists, oncolytic viruses, vaccines, TIL therapies, and CAR-T therapies.

摘要翻译： 

PD-1/PD-L1抑制剂免疫疗法已成为初诊晚期或转移性非小细胞肺癌的标准治疗方案，可单独使用或联合化疗。然而，许多肿瘤会对这些免疫治疗药物产生耐药性。因此，亟需为二线及后续治疗的转移性非小细胞肺癌患者开发更有效的疗法。本综述概述了针对此类患者正在研究的新型免疫治疗方法，总结了已完成及正在进行中的临床试验，这些试验探索了这些疗法作为单药或与PD-1/PD-L1抑制剂联合应用的疗效。涵盖的疗法包括免疫共刺激抗体、T细胞激动剂、溶瘤病毒、疫苗、肿瘤浸润淋巴细胞疗法以及CAR-T细胞疗法。

原文链接：

Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors